SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Byron Creese, Clive Ballard, Dag Aarsland, Elisabet Londos, Sally Sharp, Emma Jones, Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias, The American Journal of Geriatric Psychiatry, 2014, 22, 6, 580

    CrossRef

  2. 2
    Nicolas Morin, Vincent A. Jourdain, Thérèse Di Paolo, Modeling dyskinesia in animal models of Parkinson disease, Experimental Neurology, 2014, 256, 105

    CrossRef

  3. 3
    Benjamin Rolland, Renaud Jardri, Ali Amad, Pierre Thomas, Olivier Cottencin, Régis Bordet, Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?, BioMed Research International, 2014, 2014, 1

    CrossRef

  4. 4
    Susan H Fox, Pimavanserin as treatment for Parkinson's disease psychosis, The Lancet, 2014, 383, 9916, 494

    CrossRef

  5. 5
    Adam L. Halberstadt, Recent advances in the neuropsychopharmacology of serotonergic hallucinogens, Behavioural Brain Research, 2014,

    CrossRef

  6. 6
    Romulo Lopes Gama, Veralice Meireles Sales Bruin, Daniel Gurgel Fernandes Távora, Fábio L.S. Duran, Lia Bittencourt, Sergio Tufik, Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: A comparative voxel-based analysis, Brain and Cognition, 2014, 87, 97

    CrossRef

  7. 7
    Glenda M. Halliday, James B. Leverenz, Jay S. Schneider, Charles H. Adler, The neurobiological basis of cognitive impairment in Parkinson's disease, Movement Disorders, 2014, 29, 5
  8. 8
    Jennifer G. Goldman, Samantha Holden, Treatment of Psychosis and Dementia in Parkinson’s Disease, Current Treatment Options in Neurology, 2014, 16, 3

    CrossRef

  9. 9
    J. G. Goldman, G. T. Stebbins, V. Dinh, B. Bernard, D. Merkitch, L. deToledo-Morrell, C. G. Goetz, Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations, Brain, 2014, 137, 3, 849

    CrossRef

  10. 10
    Tiago A Mestre, Mateusz Zurowski, Susan H Fox, 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders, Expert Opinion on Investigational Drugs, 2013, 22, 4, 411

    CrossRef

  11. 11
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  12. 12
    Carolina Muguruza, José L. Moreno, Adrienne Umali, Luis F. Callado, J. Javier Meana, Javier González-Maeso, Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects, European Neuropsychopharmacology, 2013, 23, 8, 852

    CrossRef

  13. 13
    Adam L. Halberstadt, Mark A. Geyer, Serotonergic hallucinogens as translational models relevant to schizophrenia, The International Journal of Neuropsychopharmacology, 2013, 16, 10, 2165

    CrossRef

  14. 14
    Philippe Huot, Susan H. Fox, The serotonergic system in motor and non-motor manifestations of Parkinson’s disease, Experimental Brain Research, 2013, 230, 4, 463

    CrossRef

  15. 15
    Philippe Huot, Tom H. Johnston, Naomi P. Visanji, Tayyeba Darr, Donna Pires, Lili-Naz Hazrati, Jonathan M. Brotchie, Susan H. Fox, Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease, Movement Disorders, 2012, 27, 6
  16. 16
    Jennifer G Goldman, Christina L Vaughan, Christopher G Goetz, An update expert opinion on management and research strategies in Parkinson's disease psychosis, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2009

    CrossRef

  17. 17
    Jennifer G. Goldman, New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  18. 18
    Philippe Huot, Susan H Fox, Nondopaminergic treatments for Parkinson’s disease, Neurodegenerative Disease Management, 2011, 1, 6, 491

    CrossRef

  19. 19
    Daniel Weintraub, David J. Burn, Parkinson's disease: The quintessential neuropsychiatric disorder, Movement Disorders, 2011, 26, 6
  20. 20
    Michael Kometer, B. Rael Cahn, David Andel, Olivia L. Carter, Franz X. Vollenweider, The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations, Biological Psychiatry, 2011, 69, 5, 399

    CrossRef

  21. 21
    Philippe Huot, Susan H. Fox, Jonathan M. Brotchie, The serotonergic system in Parkinson's disease, Progress in Neurobiology, 2011, 95, 2, 163

    CrossRef